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Background: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of
the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic
cough vary depending on the clinical settings and the particular interests of investigators.
Objectives: The purposes of this study were first to categorize the etiology of chronic cough by its response to
systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive
cough (BRC) by the airway hyperresponsiveness.
Methods: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC.
BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the
methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the
response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the
response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to
rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no
diagnosis of eosinophilic bronchitis was made.
Results: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough
variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and
14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous
diseases. Twelve patients were undiagnosed and 11 dropped out of the study.
Conclusions: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common
cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.
Trial registration: University hospital medical information network (UMIN 000007483).
Keywords: Airway hyperresponsiveness, β2 agonist, Bronchial asthma, Cough variant asthma, Non-hyperresponsive
and β2 agonist responsive cough, Gastroesophageal reflex disease, Sinobronchial syndrome, Atopic cough,
Postnasal drip, Chronic coughBackground
Although cough is the most effective defense mechanism
for eliminating foreign materials, including numerous
pathogens from the airways, it deteriorates health-related
quality of life [1]. Therefore, cough is the most common
symptom for which patients seek medical attention [2].* Correspondence: mokazawa@fujita-hu.ac.jp
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reproduction in any medium, provided the orChung and Pavord classified the chronic cough into
corticosteroid-responsive eosinophilic airway diseases,
such as asthma (BA), cough variant asthma (CVA), eo-
sinophilic bronchitis (EB) and corticosteroid resistant
disorders such as gastro-esophageal reflux disease
(GERD), and the postnasal drip syndrome (PNDS) or
rhino-sinusitis [3]. Although all the eosinophilic airway
diseases respond to corticosteroid treatment, it is not
clear whether these disorders are separate entities, or
all one disorder with different levels of severity. Indeed,
~ 30% of CVA is reported to develop into BA [4,5],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Shimizu et al. Cough 2013, 9:4 Page 2 of 7
http://www.coughjournal.com/content/9/1/4suggesting that some types of CVA could be a precursor
of BA. On the other hand, some types of PNDS, such as
allergic rhinitis and AC, also respond to corticosteroid
[6]. Obviously, the prognosis and impact on health-
related quality of life from these conditions are quite
different from bronchial asthma, and it is not easy to de-
cide how long corticosteroid treatment should be
continued. Therefore, investigating how to differenti-
ate corticosteroid-responsive cough from other types
of cough is very worthwhile.
Etiological studies of chronic cough vary depending on
the clinical setting, the particular interest, the age of
patients, and the local definition of diseases [4,7-10]. For
example, sinobronchial syndrome (SBS) is more com-
mon in Japan, whereas GERD is less common [11].
The purposes of this study were to categorize the eti-
ology of chronic cough by its response to the systematic
diagnostic treatments starting from a high dose of an
inhaled β2 agonist, and secondarily to sub-categorize the
β2 agonist responsive cough (BRC) by airway hyperre-
sponsiveness using the methacholine challenge test.
Methods
This study was approved by the ethics committee of
Fujita Health University, and written informed consent
was obtained from all the patients who participated. One
hundred eighty-four consecutive never-smokers with no
chest radiograph abnormalities, who visited the cough
clinic of Fujita Health University complaining of chronic
cough lasting for more than 8 weeks, were enrolled. Our
cough clinic is specialized for patients whose major
complaint is chronic cough. More than 90% of the en-
rolled patients visited our clinic without referrals from
other doctors. Forty-seven were male and 137 were fe-
male. The mean age of males and females was 43 ±
14 years and 45 ± 16 years, respectively. When a patient
was taking angiotensin converting enzyme inhibitor
(ACEI) for the treatment of hypertension, the medica-
tion was changed. After obtaining a medical history,
laboratory examinations including serum IgE levels and
methacholine challenge test were performed. The
methacholine challenge test was performed according to
the guideline [12]. Briefly, the forced expiratory volume
in one second (FEV1) was measured after 2 minutes’
inhalation of saline and then the doubling dose of
methacholine was started from 0.031 mg/ml. If the final
doubling dose of 16 mg/ml was reached, a higher dose
of 20 mg/ml was added in this study. The methacholine
challenge test was diagnosed to be positive, when FEV1
decreased by more than 20% after inhalation of an in-
creasing concentration of methacholine (PC20) of 8 mg/ml
or less. Then, the stepwise diagnostic treatments were
applied (Figure 1). In each step, the patient was subject-
ively classified as a responder (RD) when the coughcompletely diminished. The patient was classified as a
partial-responder (PR) when the cough had clearly
decreased, yet persisted even with the treatment. The pa-
tient was classified as a non-responder (NR) when the
cough did not decrease at all by the treatment. In step 1,
all the patients received a metered-dose short-acting β2
agonist inhalation to start with. They received two puffs of
procaterol (20 μg), 4 times per day for 5 days using an
procaterol inhaler (Meptin Air InhalerR, Otsuka Pharma-
ceutical Co. Ltd., Japan). This is the maximal daily dose
for Japanese, and all the patients were compliant with the
protocol, although some experienced tremor or palpita-
tion. Patients who responded to procaterol by the end of
the 5th day underwent an airway reversibility test 24 hours
after cessation of the procaterol inhaler. The reversibility
test was performed according to the guideline [13]. Briefly,
forced expiratory maneuvers were repeated before and
15 minutes after nebulization of salbutamol solution
(0.65 mg/ml) for 5 minutes. The reversibility test was con-
sidered positive when FEV1 increased by more than 12%
and 200 ml from the baseline values. Thereafter, patients
who responded to procaterol received an inhaled cortico-
steroid (ICS), either fluticasone propionate (400 μg), bude-
sonide (800 μg) or beclomethasone dipropionate (400 μg)
throughout the protocol. The final assessment of step 1
was made 2 weeks after inhalation of ICS. PRs at step
1 who had postnasal drip (PND) and phlegm received
step 2-a treatment of oral administration of 400 mg
clarithromycin and 1500 mg carbocysteine per day for
14 days in addition to ICS. PRs at step2-a received
step 3 treatment of oral administration of 20 mg
rabeprazole sodium per day for 14 days on top of ICS
and step 2-a treatment. PRs at step1 who did not
have PND and phlegm skipped both step 2 treatments
and received step 3 treatment of oral administration
of 20 mg rabeprazole sodium per day on top of ICS.
For NRs at step 1 who had a previous history of
allergic diseases, increased serum total IgE levels
(>130 IU/ml) or specific IgE antibodies measured by
ELISA method (MAST26, Hitachi Chemical Co. Ltd.,
Tokyo), ICS was not used, and the step 2-b treatment of
oral administration of 10 mg cetirizine hydrochloride per
day for 14 days was applied. NRs at step 1 who had PND
and phlegm received step 2-a treatments. NRs both to
step 2-a and 2-b treatments proceeded to step 3 treatment
in which 20 mg of rabeprazole sodium alone was used per
day for 14 days.
Diagnostic criteria
RDs and PRs at step 1 were diagnosed with a β2 agonist
responsive cough (BRC). BRC patients who had PC20 of
8 mg/ml or less were classified as having hyperrespon-
sive and β2 agonist responsive cough (HBRC). Among
HBRC, patients with a previous history of bronchial




Cla rythromycin + Carbocisteine
for  14 days
Step2-a Step2-b
Cet ir izine hydroch lor ide
for  14 days
Inha led cor t icosteroid
BRC
Step 2
Step 3 Rabeprazol for  14 days
RD PR NR




Figure 1 Diagnostic treatment cascade. RD, PR and NR stand for Responder, Partial-responder and Non-responder, respectively. BRC, AC, SBS
and GERD stand for β2 agonist responsive cough, Atopic cough, Sinobronchial syndrome and Gastroesophageal reflux disease, respectively.
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or dyspnea were categorized with bronchial asthma
(BA). Patients who had a positive methacholine chal-
lenge test without any asthmatic symptoms such as
wheezing or dyspnea were diagnosed with cough variant
asthma (CVA). Patients without any asthmatic symp-
toms who failed to undergo the methacholine challenge
test were also categorized as CVA. Patients were diag-
nosed to have non-hyperresponsive BRC (NHBRC) when
they responded to the β2 agonist but their PC20 was
20 mg/ml or over. Patients with postnasal drip (PND)
and phlegm were diagnosed with sinobronchial syn-
drome (SBS) [9] when they responded to the oral admin-
istration of clarithromycin and carbocysteine. Patients
were diagnosed as atopic cough (AC) [9] when they had
either a high level of serum IgE (>130 IU/ml), or specific
IgE antibodies measured by the ELISA method, or other
allergic disorders such as allergic rhinitis or food allergy,
and responded to oral administration of cetirizine hydro-
chloride but not to inhaled β2 agonist. Patients were
diagnosed with gastroesophageal reflux disease (GERD)
when they responded to the oral administration of rabe-
prazole sodium. NRs to all the treatments at step 1–3
received further examinations such as computed tomog-
raphy, bronchoscopy, sputum bacteriologies, or sero-
logical examinations.
Statistics
RDs in step 1–3 were selected for a basic comparison.
The duration of cough, serum IgE level, a symptom of
PND, PC20, %VC, and % FEV1/FVC ratio, and flow vol-
ume parameters were compared using ANOVA and post
hoc test with Bonferroni correction. Changes in the flowvolume parameters of BRCs before and after the airway
reversibility test were compared using paired t-test. The
magnitude of change in flow volume parameters were
compared using ANOVA and post hoc test with Bonferroni
correction. A p value less than 0.05 was considered to
be significant. All the statistics were performed using
StatView5.0 (HULINKS Inc. Tokyo).
Results
Classification of chronic cough
Eleven patients dropped out of the analysis because they
did not complete the protocol. One-hundred and nine
patients were with BRC (Table 1), and eighty-six of them
received methacholine challenge tests. The others did
not undergo the tests because of increasing cough dur-
ing a test or their refusal to take the examination. No
patients showed worsening of cough after switching
from SABA to ICS in step 1 procedure. Twenty-three
patients had a previous history of bronchial asthma,
mostly during childhood, or had asthmatic symptoms
such as wheezing and were diagnosed with BA. Nineteen
of them experienced complete diminution of chronic
cough after step 1 treatment but the other 4 patients
required step 2 or 3 treatments in addition to step 1
treatment. They were diagnosed with BA + SBS or BA +
GERD. Fifty-three patients were diagnosed with CVA.
Forty-seven of them experienced complete diminution
of chronic cough after step 1 treatment but the other 6
patients were diagnosed either with CVA + SBS or with
CVA +GERD. Thirty-three patients were diagnosed with
NHBRC. Thirty of them experienced complete diminution
by step 1 treatment, while the other three were diagnosed
either with NHBRC + SBS or NHBRC +GERD.
Table 1 Classification of BRC
BRC 109 (21/88)
BA 23 (6/17) CVA 53 (8/45) NHBRC 33 (7/26)
BA 19 (5/14) CVA 47 (8/39) NHBRC 30 (7/23)
BA + SBS 2 (0/2) CVA + SBS 2 (0/2) NHBRC + SBS 2 (0/2)
BA + GERD 2 (1/1) CVA + GERD 4 (0/4) NHBRC + GERD 1 (0/1)
BA, Bronchial asthma; CVA, Cough variant asthma; NHBRC, Non-hyperresponsive and β2 agonist responsive cough; numbers within parentheses indicate males
and females.
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(Table 2). Among them, thirty-three received methacho-
line challenge tests. The others did not undergo the tests
because of increasing cough during a test or their refusal
to take the examination. Twenty-seven of 64 patients
responded to the treatment of step 2-b and were diag-
nosed with AC. The cough completely diminished in 17
of them. Others were diagnosed either with AC + SBS +
GERD or AC +GERD. Seven patients were diagnosed
with SBS because they responded to the treatment of
step 2-a. Two of them required step 3 treatment before
their cough diminished and were diagnosed with SBS +
GERD. Twelve patients were diagnosed with GERD be-
cause their cough completely diminished only by step 3
treatment. Six patients were diagnosed as Miscellaneous
(one ACEI-induced cough, 2 non-tuberculous mycobac-
terial infections, one nocardial bronchitis, one pertussis,
and one interstitial pneumonitis).
The RDs who had a single diagnosis at steps 1–3 were
selected for basic comparison (Table 3). Although the
duration of cough tended to be shorter in GERD
patients, there was no significant difference between
groups. Fifteen patients with BA, 26 with CVA, and 10
with NHBRC were atopic. There was no significant dif-
ference in serum IgE levels between these groups. A
PND symptom was significantly more prevalent in
patients with SBS than in other groups. PC20 was sig-
nificantly lower in BA and CVA than in the other
groups. There was no significant difference in %VC. The
%FEV1/FVC ratio was lower in BA than in AC, CVA
and NHBRC.
Functional differences in BRC
Among 96 RDs at step 1, 13 BAs, 10 CVAs and 19
NHBRCs received the airway reversibility test. Although
baseline PEFR and FEFR50% tended to be lower in CVAs,Table 2 Classification of non-BRC
Non-BRC 64 (20/44)
AC 27 (5/22) SBS 7 (4/3)
AC 17 (4/13) SBS 5 (3/2)
AC + SBS + GERD 1 (01) SBS + GERD 2 (1/1)
AC + GERD 9 (1/8)
AC, Atopic cough; SBS, Sinobronchial syndrome; GERD, Gastroesophageal reflux disethere were no significant differences between groups
(Table 4). PEFR increased significantly after inhalation of
salbutamol in BA and CVA patients, but not in NHBRC
patients. FEFR50% and FEFR25% significantly increased
after inhalation of salbutamol in all BRC groups. The in-
crease of PEFR of BA patients was significantly larger
than that of NHBRC (Figure 2). There was no significant
difference in the increase of FEFR50% and FEFR25% be-
tween groups (Figure 2).Discussion
In the current study, we found that chronic cough
diminished partially or completely in 59% of the patients
who used inhaled β2 agonist followed by ICS. The per-
centage of BRC was higher than that in the previous
literature [11,14], probably because we used the bron-
chodilator with a higher dose. CVA was the major cause
of chronic cough in our study, as previously reported in
Japan [15,16] although this observation is quite different
from those in Western countries [17]. In the current
study, on the other hand, there was a distinctly different
group of patients who responded to beta agonist but did
not have airway hyperresponsiveness measured by the
methacholine challenge test. We named this condition
NHBRC, and it consisted of a significantly large part of
BRC (30%) with a higher prevalence in women (Table 1).
Fujimoto et al. reported a similar phenomenon in a lim-
ited number of patients who responded to a beta agonist
without airway hyperresponsiveness [18]. Although the
airway reversibility test estimated by the change in FEV1
was not positive in all BRC patients, there was a difference
in the flow volume parameters among BA, CVA and
NHBRC. A small but significant increase was observed in
PEFR after inhalation of salbutamol in BA and CVA, but
not in NHBRC (Table 4). There was a significantGERD 12 (4/8) Miscellaneous 6 (0/6)
Undiagnosed 12 (7/5)
ase; numbers within parentheses indicate males and females.
Table 3 Basic data
BA CVA NHBRC AC SBS GERD
(n = 19) (n = 47) (n = 30) (n = 17) (n = 5) (n = 12)
Duration (days) 421 (898) 195 (428) 491 (1194) 654 (1406) 399 (396) 97 (39)
IgE ( IU/ml) 1181 (3349) 291 (583) 262 (542) 255 (383) 127 (198) 139 (168)
PND (%) 26 32 18 29 100* 17
PC20 (mg/ml) 4.347 (5.820)* 4.149 (2.944)* >20 >20 >20 >20
%VC (%) 113 (18) 106 (15) 112 (13) 118 (17) 105 (20) 115 (13)
%FEV1/FVC (%) 72 (11)* 81 (11) 83 (7) 83 (7) 75 (8) 82 (6)
Data are means (SD). Patients with a single diagnosis were selected for comparison. IgE, serum IgE level; PND (%), percentage of patients with postnasal drip; PC20,
methacholine concentration which induces a 20% decrease in the forced expiratory volume in one second (FEV1); %VC, percentage of predicted value of vital
capacity; %FEV1/FVC; FEV1/FVC ratio expressed by percentage. * p < 0.05.
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BA and NHBRC (Figure 2). These results suggest that
bronchoconstriction or increased smooth muscle tone
seem to occur less in NHBRC than in the other BRCs. On
the other hand, FEFR50% and FEFR25%, which are used for
estimating flow limitation in the peripheral airways, were
significantly increased after salbutamol inhalation in all
BRC, and the magnitude of increase among BA, CVA and
NHBRC was comparable. Since cough diminished after
procaterol inhalation in these patients with BRC, broncho-
constriction of peripheral airways may be the common
cause of chronic cough. Although bronchoconstriction
does not have a direct effect on the sensitivity of the
cough receptor in healthy subjects [19], bronchoconstric-
tion or increased bronchial tone itself may stimulate the
afferent tussive nerve, possibly by deformation of the air-
way epithelium in the peripheral airways [20]. Airway re-
modeling in BA and CVA has been documented [21], and
similar remodeling could be involved in NHBRC inducing
exaggerated airway wall deformation during bronchocon-
striction so as to cause chronic cough.
Takemura et al., who compared classical BA and CVA,
reported that 15% of CVA patients developed BA after two
year observation and that these patients had a higher IgE
level than CVA patients who did not develop BA [22].
Their results indicated that the severity of atopic status may
be associated with the development of classical asthma with
wheezing. Since patients with NHBRC had a significantly
higher IgE level as with BA and CVA, it is possible that they
could develop CVA or even BA in the future.Table 4 Flow volume parameters
BA
Before After Before
PEFR 7.51 (2.39) 7.79 (2.37)* 6.24 (1.02
FEFR50% 2.85 (1.71) 3.33 (1.93)* 2.81 (0.54
FEFR25% 0.80 (0.76) 0.92 (0.77)* 0.80 (0.54
Data are means (SD). PEFR, peak expiratory flow rate; FEFR50%, forced expiratory flow
vital capacity. * p < 0.05, NS, not significant.As shown in Table 1, there was no combination of
diagnoses between BRC and AC. Since ICS was used for
BRC in step 1 treatment, and ICS was also effective for
AC preventing this combination. Even so, the number of
AC patients in our study was far less than was reported
by Fujimura et al. [11]. According to the diagnostic cri-
teria of AC [9], patients with AC do not respond to beta
agonist. The dose of beta agonist for diagnosis, however,
is not defined. In the current study, twenty out of 33
NHBRC patients were atopic. If the patients with atopic
NHBRC in our study were undertreated with β2 ago-
nists, they could well have been diagnosed as AC. Then,
the percentage of AC would have become approximately
27%, which is close to the percentage of AC in the previ-
ous study by Fujimura et al. [11]. Non-asthmatic eosino-
philic bronchitis (NAEB), which shares similar clinical
characteristics with AC, is one of the common causes of
chronic cough [23]. NAEB is also similar to NHBRC
with respect to the effectiveness of ICS and the lack of
airway hyperresponsiveness. Since we did not measure
the eosinophil counts, it is difficult to speculate whether
eosinophilic airway inflammation was involved in
NHBRC. On the other hand, the response to beta-
agonist has not systematically been investigated in
patients with NAEB. Therefore, it seems to be very im-
portant to investigate whether there are overlaps be-
tween NAEB, AC and NHBRC, since a part of patients
with NAEB were reported to develop more serious con-
ditions such as BA or airflow limitation during the few
years of follow up [24].CVA NHBRC
After Before After
) 6.48 (1.27)* 7.67 (1.87) 7.72 (1.61)NS
) 3.05 (0.80)* 3.01 (0.66) 3.24 (0.64)*
) 1.04 (0.80)* 0.87 (0.46) 1.03 (0.50)*
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Figure 2 Changes in flow volume parameters before and after β2 agonist inhalation. PEFR, FEFR50% and FEFR25% stand for peak expiratory
flow rate, forced expiratory flow rate at 50% of vital capacity and forced expiratory flow rate at 25% of vital capacity, respectively. * P < 0.05.
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of the major causes of chronic cough [25]. The guideline
issued by the American College of Chest Physicians
suggested the use of the term “Upper airway cough syn-
drome (UACS)” instead of PND [26]. In the current
study, we did not categorize the patients as UACS since
most of the cough was diagnosed otherwise by the sys-
tematic treatment cascade. Although PND was observed
in 17-32% of BA, CVA, NHBRC, AC, and GERD
patients (Table 3), the cough diminished without H1-
antagonist in all groups except for AC. Five out of the
17 ACs had PND (Table 3) and could be diagnosed as
having UACS, since both UACS and AC respond to the
H1-antagonist, suggesting that there could be an overlap
between UACS and AC. Moreover, it is not clear that
PND itself is the independent cause of chronic cough
since PND from allergic rhinitis or rhinosinusitis is fre-
quently associated with airway disorders such as asthma
[27,28], and the cough diminishes after treatment of
asthma. O’Hara and Jones suggested that PND due to
rhinosinusitis without a coexistent chest disease is not a
predominant cause of chronic cough [29]. In the current
study, all the patients with SBS had PND, as well as a
productive cough with phlegm, and responded well to
the treatment using clarithromycin and carbocysteine
suggesting lower airway involvement. Kohno et al. classi-
fied the lower airway involvement in SBS into three cat-
egories; chronic bronchitis, bronchiectasis, and diffuse
panbronchiolitis [9]. Although it is not known why there
are more SBS patients in Japan compared with Western
countries, the genetic factors may partially contribute to
the discrepancy [30].GERD is one of the most common causes of chronic
cough and is reported to cause up to 41% of it [25]. How-
ever, Fujimura et al. reported that only 2% of chronic
cough was caused by GERD in Japan [11]. In the current
study, 6.5% of chronic cough was caused by GERD alone,
and 10.9% of patients had GERD in combination with
other disorders (Tables 1 and 2). This result shows that
the percentage of GERD is altogether similar to the results
in the literature from Western countries [25]. The preva-
lence of GERD in Japan is increasing since the end of the
1990s [31,32], possibly due to the change in dietary style
and to the decrease in Helicobacter pylori infection
brought about by antibiotics treatment. Therefore, the dis-
crepancy between the previous study by Fujimura et al.
[11] and ours could be due to the increasing occurrence
of GERD, since our study period was several years later
than theirs.
Conclusion
In the current study, we started by diagnosing chronic
cough with a bronchodilator. This method is inexpensive
and effective for categorizing the etiology of chronic
cough. The majority of patients with chronic cough had
BRC. NHBRC, a new chronic cough entity, was the major
cause of BRC. GERD is a common cause of chronic cough
in Japan, as it is in Western countries. AC and SBS are
also the causes of chronic cough in Japan.Abbreviations
BRC: β2 agonist responsive cough; HBRC: Hyperresponsive and β2 agonist
responsive cough; NHBRC: Non-hyperresponsive and β2 agonist responsive
cough; BA: Bronchial asthma; CVA: Cough variant asthma;
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